Cargando…
The challenge of pharmacological thromboprophylaxis in ICU patients: anti-FXa activity does not constitute the simple solution. Author's reply
Autores principales: | Hofmaenner, Daniel A., Singer, Mervyn |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9204360/ https://www.ncbi.nlm.nih.gov/pubmed/35713667 http://dx.doi.org/10.1007/s00134-022-06768-0 |
Ejemplares similares
-
Thromboprophylaxis in COVID-19: Anti-FXa—the Missing Factor?
por: Dutt, Tina, et al.
Publicado: (2020) -
Reply to Rappaport et al.: Anti-FXa Activity with Intermediate-Dose Thromboprophylaxis in COVID-19
por: Dutt, Tina, et al.
Publicado: (2020) -
Anti-FXa Activity with Intermediate-Dose Thromboprophylaxis in COVID-19
por: Rappaport, Stephen H., et al.
Publicado: (2020) -
“L'histoire se répète”, one size does not fit all. Author’s reply
por: Snow, Timothy Arthur Chandos, et al.
Publicado: (2021) -
Renal function in the ICU: always look both ways before initiating venous thromboprophylaxis
por: Baptista, João Pedro, et al.
Publicado: (2023)